Today In Focus

FDA approves weight loss drug Zepbound for sleep apnea

FDA approves weight loss drug Zepbound for sleep apnea


IE 11 is not supported. For an optimal experience visit our site on another browser.

  • Last-minute holiday shopping underway for millions across the US

    03:19

  • FAA temporarily bans drone flights over New York and New Jersey

    01:52

  • Now Playing

    FDA approves weight loss drug Zepbound for sleep apnea

    00:22

  • UP NEXT

    Delphi murders: Richard Allen sentenced to 130 years

    00:29

  • Mega Millions jackpot soars to a whopping $944 million

    00:31

  • New alert from CDC shows flu cases are on the rise across the US

    00:21

  • Traveling for the holidays? What to expect on roads and at airports

    02:18

  • Concerns grow in the US after attack on German Christmas market

    02:22

  • 5 dead, 200 injured in German Christmas market car attack

    01:56

  • Biden expected to sign short-term bill to keep the government open

    01:23

  • Lawmakers pass bill to avoid a government shutdown

    02:11

  • Favorite foods, movies, more: Holiday traditions by the numbers

    03:44

  • Teen diagnosed with rare cancer meets Chiefs star Isiah Pacheco

    04:07

  • See the creative way this woman told her in-laws she was pregnant

    00:52

  • $825M up for grabs as Mega Millions jackpot continues to climb

    00:27

  • Royals hold annual pre-Christmas lunch with notable absences

    02:14

  • Record-breaking holiday travel builds on the roads and at airports

    03:16

  • Luigi Mangione hit with new charges that could carry death penalty

    02:23

  • Amazon workers strike at 7 facilities, targeting holiday delivery rush

    02:25

  • How a government shutdown could impact travel, deliveries, more

    02:07

Popular weight loss drug Zepbound, which is already approved to treat obesity, now becomes the first drug to ever treat sleep apnea, a sleeping disorder that impacts nearly 40 million people.



Source

Share your love
Facebook
Twitter
Newsletter

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *